RPRX vs WST
Royalty Pharma plc vs West Pharmaceutical Services — AI-powered side-by-side comparison
RPRX
Royalty Pharma plc
56
Watch
VS
WST
West Pharmaceutical Services
74
Buy
| Metric | RPRX | WST |
|---|
| AI Score |
56
|
74
|
| Price |
$57.79
|
$351.74
|
| P/E Ratio |
23.98×
|
44.65×
|
| ROE |
11.9%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.4%
|
36.8%
|
| Debt / Equity |
1.31×
|
0.10×
|
| Dividend Yield |
1.6%
|
0.3%
|
| RSI (14) |
49.6
|
58.0
|
| Beta |
0.425
|
1.138
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for RPRX versus WST.
WST leads by 18 points.
WST scores 74/100 (Buy) versus RPRX at 56/100 (Watch).
RPRX Committee View
60% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 40.9 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 40.9 is expensive by classic value standards — Value
- EPS declining -15.9% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical